Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

Clinical trial NCT00050440 · COMPLETED

Trial details

NCT number: NCT00050440
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Endometrial Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms

Start date: 2002-07-01
Enrollment: 50

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.